

Challenges in Phase II and III Studies for T2DM

Paul Aftring, MD, PhD GlaxoSmithKline

GSK Diabetes Portfolio

Marketed Agents





- Development Agents
 - Avandaryl
 - β3 agonist ('353)
 - SGLT2 Inhibitor ('682)
 - DPP-IV Inhibitor ('093)
 - PPARpan ('954)



Phase 2 Goals and Considerations

Efficacy in selected population with disease

 Decision point for major investment

 Dose selection for pivotal trials

 Dose range (no effect to maximum)

Limited safety experience

Usually limited trial duration (<12 to 16 weeks)

Time to complete



Efficacy for diabetes treatment

Excellent surrogates (glucose, HbA1c)

Objective, continuous

Simple to design study for primary efficacy

Make use of continuous property
Less information in categorical analyses

More challenging to assess dose range

Therapeutic "window" impacts subject numbers




Phase 2 Design Approaches

- Must incorporate ethical and treatment guideline considerations
- Question to be considered: to expose fewer subjects to greater degree of hyperglycemia or more subjects to lesser degree of hyperglycemia?



Washoff current therapy



Considerations for washout studies

Ethics of discontinuing effective therapy
Duration of washout (differences between agents)

SUs with rapid washout
Metformin and TZD washout prolonged

Removal of subjects due to worsening glycemia


What criteria? (HbA1c, FPG)

No drug interactions

"Clean" background for safety evaluation



Withdraw therapy at randomization



Considerations for withdrawal studies

- Ethics of discontinuing effective therapy
 Duration of study to see full effect

 Washout of prior therapy


 Removal of subjects due to worsening glycemia

 What criteria?

 No drug interactions
- "Clean" background for safety evaluation



Add-on to existing therapy



Considerations for add-on studies

No discontinuation of effective therapy
No worsening of glycemia (fewer withdrawals)
Drug interactions must be considered
"Mixed" background for safety evaluation



Phase 2 Potential Pitfalls

- Recruiting
 - Drug naïve populations
 - Geographical difference in use of agents
- Differences in populations
 - Prior therapy
 - Starting HbA1c
- Dynamic range for endpoint
 - Entry criteria
 - Investigator bias (?)



Phase 3 Challenges

Safety evaluation (background event rates)

 Unbalanced designs
 Open label extensions

 Placebo treatment in longer duration trials

 Removal of subjects for lack of effect



Phase 3 Design Approaches

- Safety evaluation
 - Withdraw into auxiliary study if lack of efficacy
 - Allow "rescue" therapy if lack of efficacy
 - Parallel naturalistic trial with similar criteria
 - Mixed population for comparison
 - Choice of diabetes therapies to be used



Monotherapy Study Considerations

Population

- Entry HbA1c (placebo?)
- Prior therapies (monotherapy, combo therapy)
- Hyperglycemia withdrawal criteria
- Categorical efficacy analyses
 - Proportion of subjects withdrawn for hyperglycemia
 - Proportion of subjects with specified HbA1c



Add-on Studies

- Population
 - Entry HbA1c (placebo?)
 - Prior therapy
 - Limit to specific agent (doses?)
 - Conventional add-on (second line max dose)
 - First line (combination at less than maximal dose)
 - Change background at randomization
- Hyperglycemia withdrawal criteria
- Categorical efficacy analyses
 - Proportion of subjects withdrawn for hyperglycemia
 - Proportion of subjects with specified HbA1c



Comparator Studies

- Population
 - Entry HbA1c
 - Prior therapies
- Dose management
 - Forced dose titration
 - Titration to glycemic target
- Hyperglycemia withdrawal criteria
- Categorical efficacy analyses
 - Proportion of subjects withdrawn for hyperglycemia
 - Proportion of subjects with specified HbA1c



Summary

- Design considerations in Phase II and Phase III are not consistent
 - Goal is to conduct trials that acknowledge ethical and current treatment guidelines
 - Need to evaluate dose response limits phase II flexibility
- Trials for newer agents will likely use different designs than currently approved agents..

